Safeguarding the long-term health of hematopoietic stem cell donors: a continuous and evolving process to maintain donor safety and trust.
作者信息
Stroncek David, McCullough Jeffrey
出版信息
Expert Rev Hematol. 2012 Feb;5(1):1-3. doi: 10.1586/ehm.11.78.
Abstract
摘要
相似文献
1
Safeguarding the long-term health of hematopoietic stem cell donors: a continuous and evolving process to maintain donor safety and trust.保障造血干细胞捐献者的长期健康：维护捐献者安全与信任的持续且不断发展的过程。
Expert Rev Hematol. 2012 Feb;5(1):1-3. doi: 10.1586/ehm.11.78.
2
Determination of Eligibility in Related Pediatric Hematopoietic Cell Donors: Ethical and Clinical Considerations. Recommendations from a Working Group of the Worldwide Network for Blood and Marrow Transplantation Association.相关儿科造血细胞供体资格的确定：伦理与临床考量。全球血液和骨髓移植协会工作组的建议
Biol Blood Marrow Transplant. 2016 Jan;22(1):96-103. doi: 10.1016/j.bbmt.2015.08.017. Epub 2015 Aug 22.
3
Genetic editing of HLA expression in hematopoietic stem cells to broaden their human application.对造血干细胞中HLA表达进行基因编辑以拓宽其在人类中的应用。
Sci Rep. 2016 Feb 23;6:21757. doi: 10.1038/srep21757.
4
Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT).异基因造血干细胞捐献——供者结局数据的标准化评估：来自全球血液和骨髓移植网络（WBMT）的共识声明。
Bone Marrow Transplant. 2013 Feb;48(2):220-5. doi: 10.1038/bmt.2012.119. Epub 2012 Jul 9.
5
Prediction of NK Cell Licensing Level in Selection of Hematopoietic Stem Cell Donor, Initial Results.造血干细胞供体选择中自然杀伤细胞激活水平的预测：初步结果
Arch Immunol Ther Exp (Warsz). 2016 Dec;64(Suppl 1):63-71. doi: 10.1007/s00005-016-0438-2. Epub 2016 Dec 8.
6
When selecting an HLA mismatched stem cell donor consider donor immune status.在选择 HLA 不合的干细胞供体时，需考虑供体的免疫状态。
Curr Opin Immunol. 2009 Oct;21(5):538-43. doi: 10.1016/j.coi.2009.07.016. Epub 2009 Sep 6.
7
Facilitating the ethical sourcing of donor hematopoietic stem cells for cell and gene therapy research and development.促进用于细胞和基因治疗研发的供者造血干细胞的合乎伦理的来源。
Regen Med. 2024 Jun 2;19(6):317-326. doi: 10.1080/17460751.2024.2357930. Epub 2024 Jun 18.
8
Targeted recruitment of male donors for allogeneic haematopoietic cell transplantation: A review of the evidence.异基因造血细胞移植男性供体的靶向招募：证据综述
Vox Sang. 2018 May;113(4):307-316. doi: 10.1111/vox.12632. Epub 2018 Jan 22.
9
How to select the best available related or unrelated donor of hematopoietic stem cells?如何选择最佳的造血干细胞相关或无关供体？
Haematologica. 2016 Jun;101(6):680-7. doi: 10.3324/haematol.2015.141119. Epub 2016 May 31.
10
[The methods used to collect hematopoietic stem cells].[用于采集造血干细胞的方法]
Transfus Clin Biol. 2011 Apr;18(2):230-4. doi: 10.1016/j.tracli.2011.01.003. Epub 2011 Mar 11.
引用本文的文献
1
Hematopoietic Stem Cell Donors' Experiences of Information and Side-Effects During the First Year After Donation-A Swedish National Study.造血干细胞捐献者在捐献后第一年的信息及副作用体验——一项瑞典全国性研究
J Clin Apher. 2025 Aug;40(4):e70050. doi: 10.1002/jca.70050.
2
Comparison between peripheral blood progenitor cell collection on the 4 or 5 day of granulocyte colony-stimulating factor treatment in allogeneic stem cell donors: implications for hematopoietic progenitor cell apheresis guidelines.异基因干细胞供者在粒细胞集落刺激因子治疗第4天或第5天进行外周血祖细胞采集的比较：对造血祖细胞单采指南的启示
Blood Transfus. 2023 Jan;21(1):37-41. doi: 10.2450/2022.0026-22. Epub 2022 Aug 9.
3
Cell Reversal From a Differentiated to a Stem-Like State at Cancer Initiation.在癌症起始阶段细胞从分化状态逆转为干细胞样状态。
Front Oncol. 2020 Apr 15;10:541. doi: 10.3389/fonc.2020.00541. eCollection 2020.
4
We have a specific duty to maximise the safety of related donors.我们有一项特殊的职责，即最大限度地提高相关捐赠者的安全性。
Blood Transfus. 2012 Oct;10(4):407-10. doi: 10.2450/2012.0042-12. Epub 2012 Jul 12.
本文引用的文献
1
Effects of granulocyte-colony-stimulating factor on Monosomy 7 aneuploidy in healthy hematopoietic stem cell and granulocyte donors.粒细胞集落刺激因子对健康造血干细胞和粒细胞供者单体 7 非整倍体的影响。
Transfusion. 2012 Mar;52(3):537-41. doi: 10.1111/j.1537-2995.2011.03313.x. Epub 2011 Aug 29.
2
Novel agents and approaches for stem cell mobilization in normal donors and patients.新型药物和方法在正常供者和患者中的干细胞动员。
Bone Marrow Transplant. 2012 Sep;47(9):1154-63. doi: 10.1038/bmt.2011.170. Epub 2011 Aug 29.
3
Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association.关于使用生物类似物粒细胞集落刺激因子动员正常供者干细胞的担忧：世界骨髓捐献者协会的立场
Haematologica. 2011 Jul;96(7):942-7. doi: 10.3324/haematol.2011.045740.
4
Effects of granulocyte-colony stimulating factor on chromosome aneuploidy and replication asynchrony in healthy peripheral blood stem cell donors.粒细胞集落刺激因子对健康外周血造血干细胞供者染色体非整倍体和复制不同步的影响。
Blood. 2011 Sep 1;118(9):2602-8. doi: 10.1182/blood-2011-04-348508. Epub 2011 Jun 30.
5
Congenital neutropenia: diagnosis, molecular bases and patient management.先天性中性粒细胞减少症：诊断、分子基础和患者管理。
Orphanet J Rare Dis. 2011 May 19;6:26. doi: 10.1186/1750-1172-6-26.
6
Plerixafor for autologous CD34 cell mobilization.普乐沙福用于自体CD34细胞动员
Core Evid. 2011;6:23-9. doi: 10.2147/CE.S7801. Epub 2011 Feb 8.
7
Practice patterns for evaluation, consent, and care of related donors and recipients at hematopoietic cell transplantation centers in the United States.美国造血细胞移植中心评估、同意和相关供者与受者照护的实践模式。
Blood. 2010 Jun 17;115(24):5097-101. doi: 10.1182/blood-2010-01-262915. Epub 2010 Mar 12.
8
Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program.2408名非亲属外周血干细胞捐献者的不良事件：来自国家骨髓捐献项目的一项前瞻性试验结果
Blood. 2009 Apr 9;113(15):3604-11. doi: 10.1182/blood-2008-08-175323. Epub 2009 Feb 3.
9
The US National Marrow Donor Program role in unrelated donor hematopoietic cell transplantation.美国国家骨髓捐赠项目在非亲缘供者造血细胞移植中的作用。
Bone Marrow Transplant. 2008 Aug;42 Suppl 1:S3-S5. doi: 10.1038/bmt.2008.102.
10
Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program.骨髓和外周血干细胞捐献者的恢复情况及安全性概况：国家骨髓捐献项目的经验
Biol Blood Marrow Transplant. 2008 Sep;14(9 Suppl):29-36. doi: 10.1016/j.bbmt.2008.05.018.
Zotero 插件